Minimal Weight Reduction Observed with Low Doses of New Zealand’s GLP-1/GLP-2 Agonist

1. A new GLP-1/GLP-2 agonist developed in New Zealand has been tested for its weight reduction effects.
2. The study found that at the lowest doses, the agonist barely reduced weight.
3. GLP-1 and GLP-2 are hormones that regulate appetite and metabolism, and agonists of these hormones are often used in weight loss treatments.
4. The minimal weight reduction observed at low doses suggests that higher doses may be necessary for significant weight loss effects.
5. Further research is needed to determine the optimal dosage and effectiveness of this new agonist for weight loss.